World Library  
Flag as Inappropriate
Email this Article

Robalzotan

Article Id: WHEBN0022570393
Reproduction Date:

Title: Robalzotan  
Author: World Heritage Encyclopedia
Language: English
Subject: UH-301, Ebalzotan, Piclozotan, Repinotan, Sarizotan
Collection: Amines, Carboxamides, Chromenes, Organofluorides
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Robalzotan

Robalzotan
Systematic (IUPAC) name
(3R)-3-[di(cyclobutyl)amino]-8-fluoro-3,4-dihydro-2H-chromene-5-carboxamide
Clinical data
Legal status
  • Uncontrolled
Routes Oral
Identifiers
CAS number  YesY
ATC code None
PubChem
ChemSpider
UNII  YesY
Chemical data
Formula C18H23FN2O2 
Mol. mass 318.174 g/mol
 YesY   

Robalzotan (NAD-299, AZD-7371) is a selective antagonist at the 5-HT1A receptor.[1] It was shown to completely reverse the autoreceptor-mediated inhibition of serotonin release induced by the administration of selective serotonin reuptake inhibitors like citalopram in rodent studies.[2] It was subsequently investigated by AstraZeneca as a potential antidepressant but like many other 5-HT1A ligands was discontinued.[3] Later on it was researched for other indications such as irritable bowel syndrome but was dropped once again.[4]

See also

References

  1. ^ Jerning E, Svantesson GT, Mohell N. (1998). "Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist.". Eur J Pharmacol. 360 (2-3): 219–225.  
  2. ^ Arborelius L, Wallsten C, Ahlenius S, Svensson TH. (1999). "The 5-HT(1A) receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing.". Eur J Pharmacol. 382 (2): 133–138.  
  3. ^ Mucke HA. (2000). "Robalzotan AstraZeneca.". Curr Opin Investig Drugs. 1 (2): 236–240.  
  4. ^ Drossman DA, Danilewitz M, Naesdal J, Hwang C, Adler J, Silberg DG (October 2008). "Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome". The American Journal of Gastroenterology 103 (10): 2562–9.  


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.